Oncologic Drugs Advisory Committee Meeting June 2, 2006 Slides Presented at Meeting Sprycel ™(Dasatib) NDA 21-986
Welcome and Introductory Comments	Richard Pazdur, M.D., Director Office of Oncology Drug Products, OODP
Sponsor Presentation (ppt) (htm) Backup Slides (ppt) (htm) Introduction Problem Statement Clinical Program Clinical Perspective & Benefit and Risk Assessment Conclusion	Bristol-Myers Squibb Company Donna Morgan Murray, Ph.D. Neil Shah, M.D., UCLA Medical Center Claude Nicaise, M.D., VP, Global Development Hagop Kantarjian, M.D. MD Anderson Cancer Center Donna Morgan Murray, Ph.D.
FDA Presentation (ppt) (htm) Efficacy Safety	NDA 21-986 Edvardas Kaminskas, M.D., DDOP, OODP Vicki Goodman, M.D. DDOP, OODP
Open Pulic Hearing Speakers (ppt) (htm)
Questions for the Committee (ppt) (htm)